



Post Authorisation Assessments

Vetivex 11 (Hartmann's) Solution for Infusion for Cattle, Horses, Dogs and Cats Vm 10434/4080

•	19 March 2024	Dimensions of filling tubes changed.
•	25 August 2023	Correction of typo in microbiological class designation of filling room. (GB)
•	18 August 2023	Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State:– change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State. Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State:– change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State. Change to importer, batch control arrangements and quality testing for a finished product. Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible. Replacement or addition of a secondary packaging site of a finished product.
•	18 August 2023	Change in pack size within the range of the currently approved pack size. Change in pack size within the range of the currently approved pack size.
•	18 August 2023	Change in shape or dimensions of the container or:- Sterile medicinal products. Change in the specification parameters and/or limits of an active substance, starting material/intermediate/reagent used in the manufacturing process of the active substance: - Change in the testing frequency of specification parameter, from routine testing to skip or periodic testing. Change in the specification parameters and/or limits of an active substance, starting material/intermediate/reagent used in the manufacturing process of the active substance: - Change in the testing frequency of specification parameter, from routine testing to skip or periodic testing. Change to importer, batch release arrangements and quality control testing of the finished product:- Replacement or addition of a manufacturer responsible for importation and/or batch release - Other changes. Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product: - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary

		<p>packaging, for sterile veterinary medicinal products excluding biological/immunological veterinary medicinal products.</p> <p>Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: For an active substance, For a starting material/reagent/intermediate used in the manufacturing process of the active substance, or For an excipient.</p> <p>Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: For an active substance, For a starting material/reagent/intermediate used in the manufacturing process of the active substance, or For an excipient.</p> <p>Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: For an active substance, For a starting material/reagent/intermediate used in the manufacturing process of the active substance, or For an excipient.</p>
•	July 2023	<p>Change to update the specification of an active substance to comply with the current Ph. Eur.</p> <p>Submission of a new Ph. Eur. CEP from a new manufacturer. (NI)</p>
•	07 July 2023	<p>Change to comply with Ph. Eur.</p> <p>Replacement certificate of suitability from a new manufacturer. (NI)</p>
•	14 February 2023	<p>Change to update the specification of an active substance to comply with the current Ph. Eur.</p> <p>New certificate of suitability from a new manufacturer.</p>
•	17 January 2023	<p>Change to update the specification of an active substance to comply with the current Ph. Eur.</p>
•	17 January 2023	<p>Change to update the specification of an active substance to comply with the current Ph. Eur.</p> <p>New certificate of suitability from a new manufacturer.</p>
•	30 December 2022	<p>Change to comply with the current Ph. Eur. pharmacopoeia.</p> <p>Replacement certificate of suitability from a new manufacturer.</p>
•	27 November 2020	<p>Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur for the finished product.</p>
•	12 February 2019	<p>Changes to an existing pharmacovigilance system as described in the DDPS.</p>
•	01 August 2018	<p>Change in RMS from UK to IE.</p>
•	24 July 2018	<p>Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.</p>
•	12 July 2018	<p>Renewal – UK as RMS.</p>
•	14 November 2017	<p>Deletion of manufacturing site.</p> <p>Deletion of manufacturer responsible for batch release.</p>
•	16 August 2016	<p>Change of analytical method for assay on active substance to Ph. Eur. method.</p>
•	28 July 2016	<p>Minor change in the manufacturing process of an immediate release of an oral solution.</p> <p>Opportunity also taken to harmonise the QRD text with the</p>

		SPC.
•	02 December 2015	<p>Addition of a manufacturer responsible for batch release, including batch control/testing.</p> <p>Addition of a secondary packaging site.</p> <p>Submission of new or updated Ph. Eur. certificates of suitability.</p> <p>Changes in test procedure for the finished product</p> <p>Minor changes in the manufacturing process for the finished product</p> <p>Change to comply with a national pharmacopoeia of a Member State</p> <p>Addition of a manufacturing site of the finished product</p>
•	02 December 2015	Variation to change the address of the marketing authorisation holder from Dechra Limited, Jamage Industrial Estate to Dechra Limited, Snaygill Industrial Estate.
•	30 April 2015	Change in the (invented) name of the medicinal product
•	19 March 2015	To increase the shelf-life of the finished product, from 18 months to 2 years.
•	30 October 2014	Variation to introduce multi-pack sizes of 20 x 250 ml, 20 x 500 ml, 10 x 1000 ml, 4 x 3000 ml, 2 x 5000 ml, and 2 x 5000 ml combi.
•	15 May 2014	Change of active substance manufacturer.